Feeling Healthy Is Not the Same as Being Healthy: What Your Body Hides After 50

You wake up, pour your coffee, move through the day, and by evening, you feel a little tired, but nothing hurts. You would probably describe yourself as healthy. For millions of adults over 50, that self-assessment is the only health screen they use. And for a surprising number of them, it is wrong.

The human body is remarkably good at hiding trouble. It has layers of reserve capacity, meaning that entire organ systems can operate at a fraction of their original function before any symptoms appear. You can lose most of a kidney, watch half of your pancreatic insulin-producing cells disappear, or lose a third of your peak aerobic capacity, and still feel perfectly normal on a Tuesday morning. The symptoms do not arrive until the compensation runs out, which is usually years or decades after the damage begins.

That is why “I feel fine” is not a diagnosis. It is a starting point.

The Silent Cardiovascular Picture

Hypertension earned the label “silent killer” for a reason. According to the most recent Centers for Disease Control and Prevention survey data, 71.6% of US adults age 60 and older have hypertension, roughly one in four of them do not know it, and only 20.7% of all hypertensive adults have their blood pressure controlled to current targets. During the long asymptomatic phase, the left ventricle thickens, the arteries stiffen, the kidneys shed protein into the urine, and the brain accumulates silent white-matter injury. The first noticeable event may be a stroke.

Cholesterol tells a similar story when you look past the standard lipid panel. LDL cholesterol, or LDL-C, measures the amount of cholesterol carried inside particles, not the number of particles. Apolipoprotein B, or ApoB, counts every atherogenic particle your arteries actually see. In UK Biobank data pooled with two major statin trials, after accounting for ApoB, LDL-C, and triglycerides, lost their independent predictive value for heart attack. The risk tracks particle number. In 2024, the National Lipid Association issued an expert consensus formally endorsing ApoB as the superior measure of residual cardiovascular risk, yet most primary care panels still do not include it.

Lipoprotein(a), abbreviated Lp(a), is an even quieter offender. Roughly 1 in 5 adults worldwide have elevated Lp(a) levels; the trait is largely inherited, risk begins at birth, and fewer than 1% of US adults have ever been tested. Both the American Heart Association and the European Atherosclerosis Society now recommend measuring Lp(a) at least once in every adult’s lifetime.

Inflammation is the third hidden layer. High-sensitivity C-reactive protein, or hs-CRP, captures the low-grade chronic inflammation that researchers now call inflammaging. The JUPITER trial enrolled nearly 18,000 adults with “normal” LDL-C but hs-CRP of 2 mg/L or higher and found that rosuvastatin reduced heart attacks by 54% and strokes by 48%. The CANTOS trial later showed that blocking inflammation alone, without lowering cholesterol, reduced cardiovascular events. If you have never had hs-CRP measured, a meaningful piece of your risk picture is missing.

For adults aged 40-75 for whom statin decisions are uncertain, a coronary artery calcium score (CAC) provides a definitive data point. A score of zero carries an annual hard-event rate below 0.2% and is reliable for about five years. A high score identifies people whose “feeling fine” is hiding substantial plaque.

The Silent Metabolic Picture

Roughly 38% of US adults have prediabetes. Among those 65 and older, the figure rises to about 52%. More than eight in ten have no idea. Whitehall II data showed that insulin sensitivity begins to decline 13 years before a formal type 2 diabetes diagnosis, and that fasting glucose remains deceptively normal until the last 2-3 years, as the pancreas exhausts its reserve. By the time HbA1c crosses 6.5%, roughly half of beta-cell function has already been lost. A fasting insulin measurement and a HOMA-IR calculation can surface that decade of silent progression, long before HbA1c begins to move.

Fat behaves the same way. Fatty liver disease, now formally called MASLD (formerly NAFLD), affects about 30% of adults worldwide and roughly 65% of people with type 2 diabetes. Most are undiagnosed. Many people with a normal BMI also carry excess visceral and ectopic fat around the liver, pancreas, and heart, a phenotype called TOFI (thin outside, fat inside). A 2019 NHANES analysis found that only 12.2% of US adults meet criteria for optimal metabolic health. The bathroom scale cannot detect any of this. The waist-to-height ratio, which uses the simple rule of keeping your waistline smaller than half your height, performs better than BMI and remains valid as we age, sarcopenia sets in, and height begins to decline.

Muscle, Fitness, and Biological Age

Two of the most powerful mortality predictors ever studied are also two of the most neglected. The PURE study, which tracked nearly 140,000 adults across 17 countries, found that each 5 kg decrease in grip strength was associated with a 16% increase in all-cause mortality and a 17% increase in cardiovascular mortality, outperforming systolic blood pressure as a predictor. The Cleveland Clinic cohort of 122,000 adults showed that low cardiorespiratory fitness, reflected in a low VO2 max, carried a mortality risk roughly five times that of elite fitness, with effects comparable to or exceeding those of coronary disease, smoking, and diabetes.

Yet most adults over 50 have never had their grip strength measured with a handheld dynamometer or had their VO2 max tested, even indirectly. Muscle mass, meanwhile, declines 3-8% per decade after age 30 and accelerates after 50, a process called sarcopenia. Bone follows the same curve. When the two decline together, the combination, osteosarcopenia, carries hip-fracture mortality of roughly 15% at one year.

Behind all of this sits biological age, which is not the same as chronological age. DNA methylation clocks such as GrimAge and DunedinPACE estimate biological age and the pace of biological aging from a blood sample. In the landmark Dunedin cohort, biological age at chronological age 45 ranged from roughly 30 to 60, a 30-year spread. Two people who feel equally “fine” at 55 can have vastly different biological futures, and the difference is measurable.

The Silent Neurologic Picture

Cognitive decline may be the quietest of all. About one in six US adults age 45 and older reports subjective cognitive decline, and fewer than half ever mention it to a clinician. In autosomal-dominant Alzheimer’s disease, amyloid begins accumulating in the brain 15-25 years before the first symptom. Sleep is central to clearing it. Deep slow-wave sleep drives a brain-wide flushing system, the glymphatic system, that removes amyloid and other metabolic waste. Slow-wave sleep falls from about 20% of total sleep in young adults to under 5% by age 60. Obstructive sleep apnea compounds the problem and is estimated to be undiagnosed in roughly 80% of those who have it.

A Practical Starting Point

Feeling good is a starting point, not a finish line. The tests and measurements that convert that feeling into evidence are available, mostly inexpensive, and usually not ordered unless you ask. A reasonable conversation with your physician after 50 includes an advanced lipid panel with ApoB and a one-time Lp(a) measurement, hs-CRP, fasting insulin with HOMA-IR alongside HbA1c, a CAC score when the statin decision is uncertain, a DEXA scan for bone density and body composition, grip strength with a handheld dynamometer, a measured or estimated VO2 max, a STOP-BANG screen for sleep apnea, and an honest look at waist-to-height ratio.

None of these tests will prove you are unhealthy. What they will do is replace a feeling with data, and data is what allows small, early course corrections, the kind that actually change the trajectory of the next 20 or 30 years. The body is skilled at hiding slow problems. Your job after 50 is to stop letting it.

References

  1. Araújo J, Cai J, Stevens J. Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. Metab Syndr Relat Disord. 2019;17(1):46-52.
  2. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012;13(3):275-286.
  3. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795-804.
  4. Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420.
  5. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133(9):849-858.
  6. Chung F, Abdullah HR, Liao P. STOP-Bang Questionnaire: A Practical Approach to Screen for Obstructive Sleep Apnea. Chest. 2016;149(3):631-638.
  7. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019;48(1):16-31.
  8. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505-522.
  9. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946.
  10. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-273.
  11. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open. 2018;1(6):e183605.
  12. Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiol. 2022;7(3):250-256.
  13. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60.
  14. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359(21):2195-2207.
  15. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131.
  16. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647-e663.
  17. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221.
  18. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115.
  19. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377.
  20. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347.